Please assess the completion status of the following clinical trial:

Trial Title: OnabotulinumtoxinA Bladder Injection Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women and men, 18 years of age or older~* Self-reported failed conservative care of behavioral modifications and/or oral medications for the treatment of OAB~* Average urinary frequency of \> 8 voids per day as recorded on initial 3-day voiding diary~* Self-reported bladder symptoms \> 3 months~* Discontinued antimuscarinics/beta-3 agonists for \> 2 weeks prior to study enrollment. May restart antimuscarinics/beta-3 agonists if indicated \> 6 weeks after Botox injections.~* Capable of giving informed consent~* Capable and willing to follow all study-related procedures~* Previous OnabotulinumtoxinA injection at least three months prior to study enrollment.~Exclusion Criteria:~* Pregnant or planning to become pregnant during study duration~* Diagnosis of neurogenic bladder with the exception of highly functioning stroke patients~* If a patient has had a previous neuromodulation device placed, it will have to be turned off for 2 weeks for a washout period and remain off throughout the study~* Previous non-responders to onabotulinumtoxinA (BTX) therapy~* Patient cannot be receiving percutaneous nerve stimulation (PTNS) therapy. If patient is receiving PTNS, they need to stop for 1 month prior to entering the study.~* Refusal to self-catheterize or have indwelling catheter in the event of urinary retention~* Use of investigational drug/device therapy within past 4 weeks~* Participation in any clinical investigation involving or impacting gynecologic, urinary or renal function within past 4 weeks~* Current or past history of any physical condition that, in the investigator's opinion, might put the subject at risk or interfere with study results interpretation~* Pelvic radiation treatment~* Known hypersensitivity to OnabotulinumtoxinA.~* Previous infection at OnabotulinumtoxinA injection site.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3 Injection Sites (Type: EXPERIMENTAL): OnabotulinumtoxinA 100Unit injection into 3 sites throughout the bladder
- 10 Injection Sites (Type: EXPERIMENTAL): OnabotulinumtoxinA 100Unit injection into 10 sites throughout the bladder

Based on this trial design, predict the completion outcome and termination type (if applicable).